Drug Profile
Research programme: allogeneic embryo-derived motor neuron stem cell therapy - AbelZeta Pharma
Alternative Names: Embryo-derived motor neuron precursor cell therapy - AbelZeta Pharma; MNP; NPLatest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator Cellular Biomedicine Group
- Developer AbelZeta Pharma
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Motor neuron disease